首页 > 最新文献

Arterial Hypertension (Russian Federation)最新文献

英文 中文
The regulatory adaptive status in hypertensive patients with congestive heart failure with preserved left ventricular ejection fraction: the effects of fosinopril versus zofenopril 左心室射血分数保留的高血压充血性心力衰竭患者的调节适应状态:福辛普利与佐非诺普利的影响
Q4 Medicine Pub Date : 2022-03-18 DOI: 10.18705/1607-419x-2021-27-6-696-705
V. G. Tregubov, S. N. Nedvetskaya, J. Z. Shubitidze, V. Pokrovskiy
{"title":"The regulatory adaptive status in hypertensive patients with congestive heart failure with preserved left ventricular ejection fraction: the effects of fosinopril versus zofenopril","authors":"V. G. Tregubov, S. N. Nedvetskaya, J. Z. Shubitidze, V. Pokrovskiy","doi":"10.18705/1607-419x-2021-27-6-696-705","DOIUrl":"https://doi.org/10.18705/1607-419x-2021-27-6-696-705","url":null,"abstract":"","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"2 6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78633059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of membrane and circulating forms of ACE 2 in pathological processes in COVID-19 infection 膜和循环形式的ACE 2在COVID-19感染病理过程中的作用
Q4 Medicine Pub Date : 2022-03-17 DOI: 10.18705/1607-419x-2021-27-6-608-616
Y. Cheburkin, D. Sonin, A. Polozov, P. A. Mateikovich, E. Savochkina, M. Galagudza
The review analyzes milestone information about the function and pathogenic significance of human angiotensin-converting enzyme 2 (ACE2). ACE2 is involved in the development of diseases such as hypertension, malabsorption of certain amino acids in the intestine, and a new type of pneumonia COVID-19 caused by the SARSCoV-2 virus. Based on the latest literary sources, an assessment is made of the role of differential expression of receptor and soluble forms of this protein in the functioning of the renin-angiotensin-aldosterone system, as well as the mechanisms of ACE2 participation in the sequential chemical conversion of angiotensin II and its effect on the function of the cardiovascular system. The role of ACE2 in the development of inflammatory processes in the intestine and its effect on the composition of the intestinal microbiota are also discussed. In addition, the review presents most general data on the proteolytic activation of the S-glycoprotein of the SARS-CoV-2 virus and its participation, together with ACE2, in the process of virus introduction into the host cell. In conclusion, the hypothesis about autoimmune complications of COVID-19 associated with the formation of the S-glycoproteinACE2 immune complex and the production of autoantibodies is considered.
本文对人血管紧张素转换酶2 (ACE2)的功能和致病意义的里程碑性信息进行了分析。ACE2参与了高血压、肠道某些氨基酸吸收不良以及由SARSCoV-2病毒引起的新型肺炎COVID-19等疾病的发生。基于最新文献资料,本文评估了该蛋白受体和可溶性形式的差异表达在肾素-血管紧张素-醛固酮系统功能中的作用,以及ACE2参与血管紧张素II的顺序化学转化的机制及其对心血管系统功能的影响。ACE2在肠道炎症过程中的作用及其对肠道微生物群组成的影响也进行了讨论。此外,本文综述了SARS-CoV-2病毒s糖蛋白的蛋白水解激活及其与ACE2一起参与病毒进入宿主细胞过程的最一般数据。综上所述,考虑了COVID-19自身免疫性并发症与s -糖蛋白ace2免疫复合物形成和自身抗体产生相关的假设。
{"title":"The role of membrane and circulating forms of ACE 2 in pathological processes in COVID-19 infection","authors":"Y. Cheburkin, D. Sonin, A. Polozov, P. A. Mateikovich, E. Savochkina, M. Galagudza","doi":"10.18705/1607-419x-2021-27-6-608-616","DOIUrl":"https://doi.org/10.18705/1607-419x-2021-27-6-608-616","url":null,"abstract":"The review analyzes milestone information about the function and pathogenic significance of human angiotensin-converting enzyme 2 (ACE2). ACE2 is involved in the development of diseases such as hypertension, malabsorption of certain amino acids in the intestine, and a new type of pneumonia COVID-19 caused by the SARSCoV-2 virus. Based on the latest literary sources, an assessment is made of the role of differential expression of receptor and soluble forms of this protein in the functioning of the renin-angiotensin-aldosterone system, as well as the mechanisms of ACE2 participation in the sequential chemical conversion of angiotensin II and its effect on the function of the cardiovascular system. The role of ACE2 in the development of inflammatory processes in the intestine and its effect on the composition of the intestinal microbiota are also discussed. In addition, the review presents most general data on the proteolytic activation of the S-glycoprotein of the SARS-CoV-2 virus and its participation, together with ACE2, in the process of virus introduction into the host cell. In conclusion, the hypothesis about autoimmune complications of COVID-19 associated with the formation of the S-glycoproteinACE2 immune complex and the production of autoantibodies is considered.","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90913609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood pressure control, target organ protection and metabolic disorders control using a fixed combination of azilsartan medoxomil + chlorthalidone in hypertensive patients survived after severe and extremely severe COVID-19 阿齐沙坦-美多索米+氯噻酮固定联合治疗重型和极重型新冠肺炎生存期高血压患者的血压控制、靶器官保护和代谢紊乱控制
Q4 Medicine Pub Date : 2022-03-17 DOI: 10.18705/1607-419x-2021-27-6-642-652
S. Nedogoda, A. Ledyaeva, A. Salasyuk, E. Chumachek, V. Tsoma, V. Lutova, E. Popova, D. S. Vlasov, O. Bychkova, V. Labaznikova, K. Evdokimov
Objective. Evaluation of the possibility of a fixed combination of azilsartan medoxomil + chlorthalidone in additional angioprotection in patients with arterial hypertension (HTN) and high pulse wave velocity (PWV) after confirmed severe or extremely severe COVID-19 (bilateral polysegmental viral pneumonia) treated by genetically engineered biological drugs, who had not previously received combined antihypertensive therapy.Design and methods. An open observational study lasting 12 weeks included 30 patients, 28–31 days after discharge from the hospital after a severe and extremely severe COVID-19, who received or had not previously received antihypertensive therapy. Patients underwent 24-hour blood pressure (BP) monitoring, applanation tonometry (augmentation index and central BP), measurement of PWV, laboratory tests before and after prescription of a fixed combination of azilsartan medoxomil + chlorthalidone.Results. At baseline, patients showed an increase in office blood pressure to 153,06/92,2 mmHg. After treatment with a fixed combination of azilsartan medoxomil + chlorthalidone, a decrease in systolic BP by 18,47% and diastolic BP by 16,24% was observed. According to ambulatory BP monitoring, the decrease in systolic BP was 19,65% and diastolic BP — 24,68%, PWV decreased by 34,4%, augmentation index — by 9,42%, central systolic BP — by 15,48% (p < 0,05). At baseline, vascular age (VA) was increased to 44,96 years compared to the passport age of 35,03 years. After treatment, there was a significant decrease in VA to 38,74 years (p < 0,01). In addition, the levels of C-reactive protein, fibrinogen, D-dimer, glucose, blood urea nitrogen and uric acid significantly decreased.Conclusions. The fixed combination of azilsartan medoxomil + chlorthalidone provides better control of BP. It also helps to improve vascular elasticity (augmentation index, PWV, central systolic BP, decrease in VA) and to reduce post-infectious inflammation in HTN patients after a severe coronavirus infection.
目标。评价阿齐沙坦-美多索米+氯噻酮固定联合治疗先前未接受联合降压治疗的经基因工程生物药物确诊的重度或极重度COVID-19(双侧多节段病毒性肺炎)后动脉性高血压(HTN)和高脉波速度(PWV)患者额外血管保护的可能性。设计和方法。一项为期12周的开放观察性研究纳入了30例患者,这些患者在重症和极重症COVID-19患者出院后28-31天接受或未接受过降压治疗。患者在阿齐沙坦-美多索米+氯噻酮固定联合用药前后分别进行24小时血压(BP)监测、压压测量(升高指数和中心血压)、PWV测定、实验室检查。基线时,患者办公室血压升高至153,06/92,2 mmHg。阿齐沙坦+氯噻酮固定联合治疗后,收缩压下降18.47%,舒张压下降16.24%。动态血压监测显示,患者收缩压下降19.65%,舒张压下降24.68%,PWV下降34.4%,增强指数下降9.42%,中心收缩压下降15.48% (p < 0.05)。在基线时,血管年龄(VA)增加到44,96岁,而护照年龄为35,03岁。治疗后VA显著降低至38,74年(p < 0.01)。c反应蛋白、纤维蛋白原、d -二聚体、葡萄糖、血尿素氮、尿酸水平明显降低。阿齐沙坦-美多索米+氯噻酮固定联合用药对血压控制效果较好。还有助于改善HTN患者冠状病毒严重感染后的血管弹性(增强指数、PWV、中央收缩压、VA降低)和减少感染后炎症。
{"title":"Blood pressure control, target organ protection and metabolic disorders control using a fixed combination of azilsartan medoxomil + chlorthalidone in hypertensive patients survived after severe and extremely severe COVID-19","authors":"S. Nedogoda, A. Ledyaeva, A. Salasyuk, E. Chumachek, V. Tsoma, V. Lutova, E. Popova, D. S. Vlasov, O. Bychkova, V. Labaznikova, K. Evdokimov","doi":"10.18705/1607-419x-2021-27-6-642-652","DOIUrl":"https://doi.org/10.18705/1607-419x-2021-27-6-642-652","url":null,"abstract":"Objective. Evaluation of the possibility of a fixed combination of azilsartan medoxomil + chlorthalidone in additional angioprotection in patients with arterial hypertension (HTN) and high pulse wave velocity (PWV) after confirmed severe or extremely severe COVID-19 (bilateral polysegmental viral pneumonia) treated by genetically engineered biological drugs, who had not previously received combined antihypertensive therapy.Design and methods. An open observational study lasting 12 weeks included 30 patients, 28–31 days after discharge from the hospital after a severe and extremely severe COVID-19, who received or had not previously received antihypertensive therapy. Patients underwent 24-hour blood pressure (BP) monitoring, applanation tonometry (augmentation index and central BP), measurement of PWV, laboratory tests before and after prescription of a fixed combination of azilsartan medoxomil + chlorthalidone.Results. At baseline, patients showed an increase in office blood pressure to 153,06/92,2 mmHg. After treatment with a fixed combination of azilsartan medoxomil + chlorthalidone, a decrease in systolic BP by 18,47% and diastolic BP by 16,24% was observed. According to ambulatory BP monitoring, the decrease in systolic BP was 19,65% and diastolic BP — 24,68%, PWV decreased by 34,4%, augmentation index — by 9,42%, central systolic BP — by 15,48% (p < 0,05). At baseline, vascular age (VA) was increased to 44,96 years compared to the passport age of 35,03 years. After treatment, there was a significant decrease in VA to 38,74 years (p < 0,01). In addition, the levels of C-reactive protein, fibrinogen, D-dimer, glucose, blood urea nitrogen and uric acid significantly decreased.Conclusions. The fixed combination of azilsartan medoxomil + chlorthalidone provides better control of BP. It also helps to improve vascular elasticity (augmentation index, PWV, central systolic BP, decrease in VA) and to reduce post-infectious inflammation in HTN patients after a severe coronavirus infection.","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91269159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Etiopathogenetic factors and the course of hemorrhagic stroke associated with COVID-19 与COVID-19相关的发病因素和出血性卒中病程
Q4 Medicine Pub Date : 2022-03-17 DOI: 10.18705/1607-419x-2021-27-6-662-670
L. Novikova, R. F. Latypova, A. Novikov
Background. Acute stroke is a highly specific neurological symptom in the acute phase of COVID-19. Hemorrhagic stroke (HS) is an infrequent, but life-threatening complication of COVID-19.Objective. To analyze etiopathogenetic factors and the course of HS associated with COVID-19.Design and methods. A retrospective analysis of 27 medical histories of patients with HS associated with COVID-19 (the main group) and 14 medical histories of patients with HS not related to COVID-19 (the control group) was performed. In the main group, COVID-19 was confirmed by the positive polymerase chain reaction method. HS developed before COVID-19 symptoms in 10 (37,04%) patients and after 4–16 days of COVID-19 symptoms onset in 17 (62,96%) patients.Results. Our study indicates significant differences in blood pressure (BP), respiratory system parameters, laboratory data, neuroimaging data in patients of the main and control groups. Coagulopathy, thrombocytopenia, hypoxia, and the renal and hepatic failure play a significant role in the development of HS associated with COVID-19 compared to the classic HS (without COVID-19), where hypertension seems to be the important. At the same time BP is significantly lower in the main group.Conclusions. The etiopathogenetic factors and the course of HS associated with COVID-19 require pathogenetically different therapy compared to HS without COVID-19.
背景。急性卒中是COVID-19急性期高度特异性的神经系统症状。出血性中风(HS)是covid -19罕见但危及生命的并发症。分析与COVID-19相关的HS发病因素及病程。设计和方法。回顾性分析27例与COVID-19相关的HS患者(主要组)和14例与COVID-19无关的HS患者(对照组)的病史。主组经聚合酶链反应阳性确诊。10例(37,04%)患者在COVID-19症状出现前出现HS, 17例(62,96%)患者在COVID-19症状出现4-16天后出现HS。我们的研究表明,实验组和对照组患者的血压(BP)、呼吸系统参数、实验室数据、神经影像学数据存在显著差异。凝血功能障碍、血小板减少症、缺氧、肾功能和肝功能衰竭在与COVID-19相关的HS的发展中起重要作用,而与没有COVID-19的经典HS相比,高血压似乎是重要的。同时,主组血压明显降低。与无COVID-19的HS相比,与COVID-19相关的HS的发病因素和病程需要不同的病理治疗。
{"title":"Etiopathogenetic factors and the course of hemorrhagic stroke associated with COVID-19","authors":"L. Novikova, R. F. Latypova, A. Novikov","doi":"10.18705/1607-419x-2021-27-6-662-670","DOIUrl":"https://doi.org/10.18705/1607-419x-2021-27-6-662-670","url":null,"abstract":"Background. Acute stroke is a highly specific neurological symptom in the acute phase of COVID-19. Hemorrhagic stroke (HS) is an infrequent, but life-threatening complication of COVID-19.Objective. To analyze etiopathogenetic factors and the course of HS associated with COVID-19.Design and methods. A retrospective analysis of 27 medical histories of patients with HS associated with COVID-19 (the main group) and 14 medical histories of patients with HS not related to COVID-19 (the control group) was performed. In the main group, COVID-19 was confirmed by the positive polymerase chain reaction method. HS developed before COVID-19 symptoms in 10 (37,04%) patients and after 4–16 days of COVID-19 symptoms onset in 17 (62,96%) patients.Results. Our study indicates significant differences in blood pressure (BP), respiratory system parameters, laboratory data, neuroimaging data in patients of the main and control groups. Coagulopathy, thrombocytopenia, hypoxia, and the renal and hepatic failure play a significant role in the development of HS associated with COVID-19 compared to the classic HS (without COVID-19), where hypertension seems to be the important. At the same time BP is significantly lower in the main group.Conclusions. The etiopathogenetic factors and the course of HS associated with COVID-19 require pathogenetically different therapy compared to HS without COVID-19.","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"22-23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73985037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of renin-angiotensin-aldosterone system blockers on the course of COVID-19 in patients with arterial hypertension 肾素-血管紧张素-醛固酮系统阻滞剂对动脉高血压患者COVID-19病程的影响
Q4 Medicine Pub Date : 2022-03-17 DOI: 10.18705/1607-419x-2021-27-6-653-661
T. Sveklina, M. Tyuryupov, V. A. Medvedeva, S. Shustov, A. Kuchmin, V. Kozlov
Objective. To determine the presence or absence of the effect of therapy with renin-angiotensin-aldosterone system (RAAS) blockers in patients with COVID-19.Design and methods. We examined 57 patients who were treated in a medical unit at the FGAU CEC “Patriot” in the period from October to November 2020, with the diagnosis of “New coronavirus infection” and differed in the prescribed antihypertensive therapy. In group 1, drugs that affect the RAAS were used to treat hypertension before COVID-19 onset and during the treatment of COVID-19. In group 2, other drugs were used as the main antihypertensive agents before and during treatment for COVID-19. The severity of pneumonia in patients according to the results of computed tomography was 1–2. The patients were monitored for anthropometric indicators, body temperature, and laboratory data.Results. Groups 1 and 2 are comparable, differing only by height, but not by body mass index. The duration of treatment in group 2 was 1–2 days shorter than in group 1, but the result is not statistically significant due to the small sample. Thus, the hypothesis that differences between previous and ongoing antihypertensive therapy throughout the COVID-19 treatment period may affect the course and effectiveness of treatment has not been confirmed.Conclusions. Concomitant antihypertensive therapy with RAAS blockers does not alter the course of COVID-19 infection in patients. The duration of COVID-19 in patients receiving RAAS system blockers may be one day longer than for patients receiving other antihypertensive therapy.
目标。目的:确定肾素-血管紧张素-醛固酮系统(RAAS)阻滞剂治疗COVID-19患者的效果。设计和方法。我们调查了2020年10月至11月期间在FGAU CEC“爱国者”医疗单位就诊的57例诊断为“新型冠状病毒感染”且处方降压治疗不同的患者。在1组中,在COVID-19发病前和治疗期间使用影响RAAS的药物治疗高血压。第二组患者在COVID-19治疗前和治疗期间使用其他药物作为主要降压药物。根据计算机断层扫描结果,患者肺炎的严重程度为1-2。监测患者的人体测量指标、体温和实验室数据。第一组和第二组具有可比性,只是身高不同,而身体质量指数不同。2组治疗时间比1组短1 ~ 2天,但由于样本量小,结果无统计学意义。因此,在COVID-19治疗期间,既往和正在进行的降压治疗之间的差异可能会影响治疗的过程和有效性的假设尚未得到证实。同时使用RAAS阻滞剂抗高血压治疗不会改变患者的COVID-19感染过程。接受RAAS系统阻滞剂治疗的患者的COVID-19持续时间可能比接受其他降压治疗的患者长一天。
{"title":"The effect of renin-angiotensin-aldosterone system blockers on the course of COVID-19 in patients with arterial hypertension","authors":"T. Sveklina, M. Tyuryupov, V. A. Medvedeva, S. Shustov, A. Kuchmin, V. Kozlov","doi":"10.18705/1607-419x-2021-27-6-653-661","DOIUrl":"https://doi.org/10.18705/1607-419x-2021-27-6-653-661","url":null,"abstract":"Objective. To determine the presence or absence of the effect of therapy with renin-angiotensin-aldosterone system (RAAS) blockers in patients with COVID-19.Design and methods. We examined 57 patients who were treated in a medical unit at the FGAU CEC “Patriot” in the period from October to November 2020, with the diagnosis of “New coronavirus infection” and differed in the prescribed antihypertensive therapy. In group 1, drugs that affect the RAAS were used to treat hypertension before COVID-19 onset and during the treatment of COVID-19. In group 2, other drugs were used as the main antihypertensive agents before and during treatment for COVID-19. The severity of pneumonia in patients according to the results of computed tomography was 1–2. The patients were monitored for anthropometric indicators, body temperature, and laboratory data.Results. Groups 1 and 2 are comparable, differing only by height, but not by body mass index. The duration of treatment in group 2 was 1–2 days shorter than in group 1, but the result is not statistically significant due to the small sample. Thus, the hypothesis that differences between previous and ongoing antihypertensive therapy throughout the COVID-19 treatment period may affect the course and effectiveness of treatment has not been confirmed.Conclusions. Concomitant antihypertensive therapy with RAAS blockers does not alter the course of COVID-19 infection in patients. The duration of COVID-19 in patients receiving RAAS system blockers may be one day longer than for patients receiving other antihypertensive therapy.","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"139 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89045680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced renal function in hypertension in young adults: a systematic review 青壮年高血压患者肾功能降低:系统综述
Q4 Medicine Pub Date : 2022-03-17 DOI: 10.18705/1607-419x-2021-27-6-617-627
A. Khudiakova, Y. Ragino
Objective. The aim of the systematic review was to find an answer to the question: «does an increased blood pressure affect kidney function at young age?».Design and methods. The following key words were used to search for relevant publications: “hypertensive nephropathy”, “reduction of glomerular filtration rate in arterial hypertension” in Russian and English. We used “eLIBRARY.RU — SCIENTIFIC ELECTRONIC LIBRARY” and PubMed.gov databases. The inclusion criteria were the young age of the examined patients (from 18 to 44 years), the absence of concomitant pathology. The analysis included only publications of the last 5 years (2015-2020).Results. A total of 18 articles were selected from Russian and international databases that meet inclusion criteria.Conclusions. Based on the analysis of the literature of the last 5 years we assume that increase in blood pressure disrupts kidney function in young people. However, the current data a number of limitations. Until now, gender characteristics, risk factors for decreased renal function in hypertension in young people, and most importantly, the pathogenetic basis of renal dysfunction remain unclear.
目标。系统回顾的目的是找到问题的答案:“血压升高会影响年轻时的肾功能吗?”设计和方法。使用以下关键词搜索相关文献:俄文和英文的“高血压肾病”、“动脉高血压中肾小球滤过率的降低”。我们使用了“图书馆”。RU -科学电子图书馆”和PubMed.gov数据库。纳入标准为年龄小(18 - 44岁),无伴发病理。本分析仅包括最近5年(2015-2020)的出版物。从俄罗斯和国际数据库中选取符合纳入标准的文献共18篇。根据过去5年的文献分析,我们假设血压升高会破坏年轻人的肾功能。然而,目前的数据存在一些局限性。到目前为止,对青少年高血压患者的性别特征、肾功能下降的危险因素,以及最重要的,肾功能障碍的发病基础仍不清楚。
{"title":"Reduced renal function in hypertension in young adults: a systematic review","authors":"A. Khudiakova, Y. Ragino","doi":"10.18705/1607-419x-2021-27-6-617-627","DOIUrl":"https://doi.org/10.18705/1607-419x-2021-27-6-617-627","url":null,"abstract":"Objective. The aim of the systematic review was to find an answer to the question: «does an increased blood pressure affect kidney function at young age?».Design and methods. The following key words were used to search for relevant publications: “hypertensive nephropathy”, “reduction of glomerular filtration rate in arterial hypertension” in Russian and English. We used “eLIBRARY.RU — SCIENTIFIC ELECTRONIC LIBRARY” and PubMed.gov databases. The inclusion criteria were the young age of the examined patients (from 18 to 44 years), the absence of concomitant pathology. The analysis included only publications of the last 5 years (2015-2020).Results. A total of 18 articles were selected from Russian and international databases that meet inclusion criteria.Conclusions. Based on the analysis of the literature of the last 5 years we assume that increase in blood pressure disrupts kidney function in young people. However, the current data a number of limitations. Until now, gender characteristics, risk factors for decreased renal function in hypertension in young people, and most importantly, the pathogenetic basis of renal dysfunction remain unclear.","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86955418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Features of functional adaptation of the cardiovascular system in athletes with different levels of blood pressure 不同血压水平运动员心血管系统功能适应特点
Q4 Medicine Pub Date : 2022-03-17 DOI: 10.18705/1607-419x-2021-27-6-671-682
E. Mestnikova, F. A. Zakharova, N. Makharova, I. A. Pinigina
Objective. To assess cardiovascular functional adaptation in athletes with different levels of blood pressure (BP) in the Republic of Sakha (Yakutia).Design and methods. We examined 147 professional athletes of high sportsmanship (average age 22 (18; 26) years), cyclic and speed-weightlifting sports. All athletes underwent anthropometry, measurement of office BP and daily BP monitoring, exercise test (PWC170), with determination of maximum oxygen consumption, assessment of the reserve capacity of the cardiovascular system, echocardiography.Results. Masked hypertension (MH) was detected in 40,8% of athletes, normal BP in 59,2%. All athletes showed a high tolerance to physical activity; athletes with MH showed high indices of left ventricular (LV) wall thickness and myocardial mass index compared with athletes with normal BP. The athletes with MH achieve a high level of physical performance due to a less efficient hemodynamic mechanism and energy-intense regimen. A positive correlation was found between LV wall thickness and indicators of cardiovascular functional reserves.Conclusions. MH was detected in 40,8% athletes. In athletes with different BP levels, quantitative and qualitative differences in ensuring physical performance are expressed by the ratio between the “initial” (rest) and “maximum” (test with physical load) indicators of the functional state. Thus, in athletes with MH, inefficient hemodynamic and energy-intensive processes can lead to overstrain of the cardiovascular system. Indicators of functional reserves of the cardiovascular system positively correlate with indicators of LV myocardial wall thickness and myocardial mass index, which may indirectly indicate the relation between cardiovascular overstrain in athletes with MH and target organ damage (LV hypertrophy).
目标。评估萨哈共和国(雅库特)不同血压水平运动员的心血管功能适应。设计和方法。我们调查了147名具有高度体育精神的职业运动员(平均年龄22岁;26岁),循环和速度举重运动。所有运动员均进行了人体测量、办公室血压测量和每日血压监测、运动试验(PWC170)、最大耗氧量测定、心血管系统储备容量评估、超声心动图检查。隐匿性高血压40.8%,血压正常59.2%。所有运动员都表现出对体育活动的高耐受性;与血压正常的运动员相比,MH运动员左室壁厚和心肌质量指数较高。由于低效率的血液动力学机制和高强度的运动方案,MH运动员获得了高水平的身体表现。左室壁厚度与心血管功能储备指标呈正相关。运动员中检出MH 40.8%。在不同血压水平的运动员中,在保证体能表现方面的定量和定性差异表现为功能状态的“初始”(休息)和“最大”(负荷测试)指标的比值。因此,在患有MH的运动员中,低效率的血液动力学和能量密集型过程可能导致心血管系统过度紧张。心血管系统功能储备指标与左室心肌壁厚、心肌质量指数等指标正相关,可间接提示MH运动员心血管过度劳损与靶器官损伤(左室肥厚)的关系。
{"title":"Features of functional adaptation of the cardiovascular system in athletes with different levels of blood pressure","authors":"E. Mestnikova, F. A. Zakharova, N. Makharova, I. A. Pinigina","doi":"10.18705/1607-419x-2021-27-6-671-682","DOIUrl":"https://doi.org/10.18705/1607-419x-2021-27-6-671-682","url":null,"abstract":"Objective. To assess cardiovascular functional adaptation in athletes with different levels of blood pressure (BP) in the Republic of Sakha (Yakutia).Design and methods. We examined 147 professional athletes of high sportsmanship (average age 22 (18; 26) years), cyclic and speed-weightlifting sports. All athletes underwent anthropometry, measurement of office BP and daily BP monitoring, exercise test (PWC170), with determination of maximum oxygen consumption, assessment of the reserve capacity of the cardiovascular system, echocardiography.Results. Masked hypertension (MH) was detected in 40,8% of athletes, normal BP in 59,2%. All athletes showed a high tolerance to physical activity; athletes with MH showed high indices of left ventricular (LV) wall thickness and myocardial mass index compared with athletes with normal BP. The athletes with MH achieve a high level of physical performance due to a less efficient hemodynamic mechanism and energy-intense regimen. A positive correlation was found between LV wall thickness and indicators of cardiovascular functional reserves.Conclusions. MH was detected in 40,8% athletes. In athletes with different BP levels, quantitative and qualitative differences in ensuring physical performance are expressed by the ratio between the “initial” (rest) and “maximum” (test with physical load) indicators of the functional state. Thus, in athletes with MH, inefficient hemodynamic and energy-intensive processes can lead to overstrain of the cardiovascular system. Indicators of functional reserves of the cardiovascular system positively correlate with indicators of LV myocardial wall thickness and myocardial mass index, which may indirectly indicate the relation between cardiovascular overstrain in athletes with MH and target organ damage (LV hypertrophy).","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73089214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary artery denervation for pulmonary hypertension: a systematic review and meta-analysis of clinical studies 肺动脉去神经支配治疗肺动脉高压:临床研究的系统回顾和荟萃分析
Q4 Medicine Pub Date : 2022-03-17 DOI: 10.18705/1607-419x-2021-27-6-628-641
L. Korobchenko, N. Goncharova, H. I. Condori Leandro, A. Vakhrushev, E. Andreeva, O. Moiseeva, E. N. Mikhaylov
Objective. To analyze the results of clinical studies on pulmonary artery denervation (PADN) for pulmonary hypertension treatment.Design and methods. Study search was conducted in PubMed/Medline, Cochrane, Elibrary databases. The analysis included studies of surgical and transcatheter PADN. To assess the effectiveness of the PADN procedure, a mean pulmonary artery pressure (mPAP) and a 6-minute walk test distance (6-MWT) were selected. For each study, the mean change in mPAP and 6-MWT were calculated and included in the analysis.Results. A total of 8 studies were analyzed: 4 randomized and 4 observational, 320 patients were included in the study, of which 222 patients underwent PADN. The etiology of pulmonary hypertension (PH) was different in each study and included patients with idiopathic PH, PH associated with heart failure, chronic thromboembolic PH. According to the combined data analysis, mPAP decreased in all studies, and the overall change in mPAP was –8,59 [95 % confidence interval (CI) –10,96; –6,23]. The average increase in 6-MWT among studies was 60,00 [95 % CI 35,74; 84,27].Conclusions. Despite serious limitations (a small number of studies and subjects enrolled, non-randomized design of a half of the studies, high heterogeneity of data), this analysis demonstrated the association of the PADN procedure with a decrease in pulmonary artery pressure and prolongation of the 6-minute walking distance in patients with PH of various etiologies.
目标。目的分析肺动脉去神经支配治疗肺动脉高压的临床研究结果。设计和方法。研究检索在PubMed/Medline, Cochrane, library数据库中进行。分析包括手术和经导管PADN的研究。为了评估PADN手术的有效性,我们选择了平均肺动脉压(mPAP)和6分钟步行测试距离(6-MWT)。对于每项研究,计算mPAP和6-MWT的平均变化并将其纳入分析。共分析8项研究:4项随机研究和4项观察研究,共纳入320例患者,其中222例患者接受了PADN。肺动脉高压(PH)的病因在每项研究中都不同,包括特发性PH、PH与心力衰竭相关、慢性血栓栓塞性PH。根据综合数据分析,所有研究的mPAP均下降,mPAP的总体变化为- 8,59[95%置信区间(CI) - 10,96;6日,23)。研究中6-MWT的平均增加为60000例[95% CI 35,74;84年,27].Conclusions。尽管存在严重的局限性(研究和受试者数量较少,一半研究的非随机设计,数据的高度异质性),该分析表明,PADN手术与各种病因的PH患者肺动脉压降低和6分钟步行距离延长有关。
{"title":"Pulmonary artery denervation for pulmonary hypertension: a systematic review and meta-analysis of clinical studies","authors":"L. Korobchenko, N. Goncharova, H. I. Condori Leandro, A. Vakhrushev, E. Andreeva, O. Moiseeva, E. N. Mikhaylov","doi":"10.18705/1607-419x-2021-27-6-628-641","DOIUrl":"https://doi.org/10.18705/1607-419x-2021-27-6-628-641","url":null,"abstract":"Objective. To analyze the results of clinical studies on pulmonary artery denervation (PADN) for pulmonary hypertension treatment.Design and methods. Study search was conducted in PubMed/Medline, Cochrane, Elibrary databases. The analysis included studies of surgical and transcatheter PADN. To assess the effectiveness of the PADN procedure, a mean pulmonary artery pressure (mPAP) and a 6-minute walk test distance (6-MWT) were selected. For each study, the mean change in mPAP and 6-MWT were calculated and included in the analysis.Results. A total of 8 studies were analyzed: 4 randomized and 4 observational, 320 patients were included in the study, of which 222 patients underwent PADN. The etiology of pulmonary hypertension (PH) was different in each study and included patients with idiopathic PH, PH associated with heart failure, chronic thromboembolic PH. According to the combined data analysis, mPAP decreased in all studies, and the overall change in mPAP was –8,59 [95 % confidence interval (CI) –10,96; –6,23]. The average increase in 6-MWT among studies was 60,00 [95 % CI 35,74; 84,27].Conclusions. Despite serious limitations (a small number of studies and subjects enrolled, non-randomized design of a half of the studies, high heterogeneity of data), this analysis demonstrated the association of the PADN procedure with a decrease in pulmonary artery pressure and prolongation of the 6-minute walking distance in patients with PH of various etiologies.","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78056963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of associations of hypertension with 16 genetic markers selected according to genome-wide studies 根据全基因组研究选择的16个遗传标记与高血压的关联分析
Q4 Medicine Pub Date : 2022-03-16 DOI: 10.18705/1607-419x-2022-28-1-46-57
E. Mazdorova, V. Maksimov, П. S. Orlov, S. Shakhmatov, A. Ryabikov, M. Voevoda, S. Malyutina
The multifactorial genesis of hypertension (HTN) enforced the investigation of genetically determined component of its etiopathogenesis in various populations.The aim of present work is to assess the associations between blood pressure (BP) and HTN and polymorphism of a number of genetic markers identified according to GWAS data, in a case-control study based on Siberian population cohort. Design and methods. Design of the work—case-control study in the groups aged 45–69 years old based on a caucasoid population cohort (Novosibirsk). The group of cases included HTN subjects with established diagnosis of HTN under the age of 50 (n = 346)). The control included subjects matched by sex and age to cases, and having at least 2 examinations (6 months apart) with BP levels not exceeding “normal” BP by ESH, 2018 (n = 168). A total of 514 people were included in the analysis. We used standardized epidemiological methods to assess HTN and cardiovascular diseases. Single nucleotide polymorphisms (SNPs) were tested using real-time PCR (ABI 7900HT). The analysis included 16 markers identified in GWAS studies (rs11646213, rs17367504, rs11191548, rs12946454, rs16998073, rs1530440, rs653178, rs1378942, rs1004467, rs381815, rs2681492, rs2681472, rs3184504, rs2384550, rs6495122, rs6773957).Results. For the polymorphism rs1378942 of cytoplasmic tyrosine kinase gene (CSK), in a multivariable-adjusted logistic regression, the carriers of the AC/CC vs. AA genotypes had odds ratio (OR) of HTN of 1,51 (p = 0,043) independent of age and sex; this excess risk was partly explained by the impact of body mass index (BMI). With respect to the quantitative phenotype, women carrying the AA genotype had diastolic BP (DBP) value 5 mm Hg lower than carriers of AC/CC genotypes (p = 0,026). In a multivariable-adjusted analysis, the polymorphism rs653178 of ataxin 2 gene (ATXN2) was associated with HTN independent of age and BMI (СС vs ТТ/ТС; OR = 0,61; p = 0,022); this relationship was realized due to the contribution of men (p = 0,027). With respect to the quantitative phenotype, in the multivariable analysis, the carriers of СС genotype had DBP value lower than those with ТТ/ТС (p = 0,022) independent of age and BMI, and due to the contribution of men. In a multivariableadjusted analysis, the polymorphism rs6773957 of adiponectin gene (ADIPOQ) was associated with HTN in women regardless of age and BMI (GG v. AA/AG; OR = 0,29; p = 0,001). In unadjusted analysis, we found the association between polymorphism rs2384550 of T box transcription factor gene (TBX3) and the level of systolic BP (SBP) in men (p = 0,043); when comparing homozygous groups, the level of SBP was significantly higher among carriers of the AA genotype versus GG (p = 0,013), but this association was attenuated to insignificant in in a multivariate analysis.Conclusions. In a case-control study based on Siberian population sample, we found the associations between qualitative and quantitative phenotypes of BP/HTN an
高血压(HTN)的多因素发病机制迫使人们在不同人群中对其发病机制的遗传决定因素进行研究。本研究的目的是在一项基于西伯利亚人群队列的病例对照研究中,评估血压(BP)和HTN之间的关系以及根据GWAS数据确定的一些遗传标记的多态性。设计和方法。基于高加索人群队列(新西伯利亚)的45-69岁人群的工作病例对照研究设计。本组病例包括年龄在50岁以下且确诊为HTN的HTN患者(n = 346)。对照组包括按性别和年龄与病例匹配的受试者,并且至少有2次检查(间隔6个月),到2018年ESH时血压水平不超过“正常”血压(n = 168)。共有514人被纳入分析。采用标准化流行病学方法评估HTN与心血管疾病的关系。采用实时荧光定量PCR (ABI 7900HT)检测单核苷酸多态性。分析包括在GWAS研究中鉴定的16个标记(rs11646213、rs17367504、rs11191548、rs12946454、rs16998073、rs1530440、rs653178、rs1378942、rs1004467、rs381815、rs2681492、rs2681472、rs3184504、rs2384550、rs6495122、rs6773957)。胞质酪氨酸激酶基因(CSK)多态性rs1378942,经多变量校正logistic回归分析,AC/CC与AA基因型携带者HTN的比值比(OR)为1,51 (p = 0,043),与年龄和性别无关;身体质量指数(BMI)的影响部分解释了这种额外的风险。在定量表型方面,携带AA基因型的女性舒张压(DBP)值比携带AC/CC基因型的女性低5 mm Hg (p = 0.026)。在一项多变量调整分析中,ataxin 2基因(ATXN2)多态性rs653178与HTN相关,与年龄和BMI无关(СС vs ТТ/ТС;Or = 0,61;P = 0.022);这种关系是由于男性的贡献而实现的(p = 0.027)。在定量表型方面,在多变量分析中,由于男性的贡献,与年龄和BMI无关,СС基因型携带者的DBP值低于ТТ/ТС基因型携带者(p = 0.022)。在一项多变量调整分析中,脂联素基因(ADIPOQ)多态性rs6773957与女性HTN相关,与年龄和BMI无关(GG vs . AA/AG;Or = 0,29;P = 0.001)。在未校正分析中,我们发现T盒转录因子基因(TBX3)多态性rs2384550与男性收缩压(SBP)水平存在相关性(p = 0.043);当比较纯合子组时,AA基因型携带者的收缩压水平明显高于GG (p = 0,013),但在多因素分析中,这种关联减弱到不显著。在西伯利亚人群样本的病例对照研究中,我们发现BP/HTN的定性和定量表型与4个snp (CSK、ATXN2、ADIPOQ、TBX3基因)多态性存在相关性。我们的数据重复了在全基因组研究中获得的一些积极结果,我们获得了以前没有令人信服的新关联的证据,以及HTN与许多分子标记之间关联的背景依赖性。
{"title":"Analysis of associations of hypertension with 16 genetic markers selected according to genome-wide studies","authors":"E. Mazdorova, V. Maksimov, П. S. Orlov, S. Shakhmatov, A. Ryabikov, M. Voevoda, S. Malyutina","doi":"10.18705/1607-419x-2022-28-1-46-57","DOIUrl":"https://doi.org/10.18705/1607-419x-2022-28-1-46-57","url":null,"abstract":"The multifactorial genesis of hypertension (HTN) enforced the investigation of genetically determined component of its etiopathogenesis in various populations.The aim of present work is to assess the associations between blood pressure (BP) and HTN and polymorphism of a number of genetic markers identified according to GWAS data, in a case-control study based on Siberian population cohort. Design and methods. Design of the work—case-control study in the groups aged 45–69 years old based on a caucasoid population cohort (Novosibirsk). The group of cases included HTN subjects with established diagnosis of HTN under the age of 50 (n = 346)). The control included subjects matched by sex and age to cases, and having at least 2 examinations (6 months apart) with BP levels not exceeding “normal” BP by ESH, 2018 (n = 168). A total of 514 people were included in the analysis. We used standardized epidemiological methods to assess HTN and cardiovascular diseases. Single nucleotide polymorphisms (SNPs) were tested using real-time PCR (ABI 7900HT). The analysis included 16 markers identified in GWAS studies (rs11646213, rs17367504, rs11191548, rs12946454, rs16998073, rs1530440, rs653178, rs1378942, rs1004467, rs381815, rs2681492, rs2681472, rs3184504, rs2384550, rs6495122, rs6773957).Results. For the polymorphism rs1378942 of cytoplasmic tyrosine kinase gene (CSK), in a multivariable-adjusted logistic regression, the carriers of the AC/CC vs. AA genotypes had odds ratio (OR) of HTN of 1,51 (p = 0,043) independent of age and sex; this excess risk was partly explained by the impact of body mass index (BMI). With respect to the quantitative phenotype, women carrying the AA genotype had diastolic BP (DBP) value 5 mm Hg lower than carriers of AC/CC genotypes (p = 0,026). In a multivariable-adjusted analysis, the polymorphism rs653178 of ataxin 2 gene (ATXN2) was associated with HTN independent of age and BMI (СС vs ТТ/ТС; OR = 0,61; p = 0,022); this relationship was realized due to the contribution of men (p = 0,027). With respect to the quantitative phenotype, in the multivariable analysis, the carriers of СС genotype had DBP value lower than those with ТТ/ТС (p = 0,022) independent of age and BMI, and due to the contribution of men. In a multivariableadjusted analysis, the polymorphism rs6773957 of adiponectin gene (ADIPOQ) was associated with HTN in women regardless of age and BMI (GG v. AA/AG; OR = 0,29; p = 0,001). In unadjusted analysis, we found the association between polymorphism rs2384550 of T box transcription factor gene (TBX3) and the level of systolic BP (SBP) in men (p = 0,043); when comparing homozygous groups, the level of SBP was significantly higher among carriers of the AA genotype versus GG (p = 0,013), but this association was attenuated to insignificant in in a multivariate analysis.Conclusions. In a case-control study based on Siberian population sample, we found the associations between qualitative and quantitative phenotypes of BP/HTN an","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75506092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of arterial hypertension in women after delivery (a literature review) 产后女性动脉高血压的处理(文献综述)
Q4 Medicine Pub Date : 2022-03-11 DOI: 10.18705/1607-419x-2022-28-2-126-146
I. Gaisin, A. Iskhakova, E. Smirnova
{"title":"Management of arterial hypertension in women after delivery (a literature review)","authors":"I. Gaisin, A. Iskhakova, E. Smirnova","doi":"10.18705/1607-419x-2022-28-2-126-146","DOIUrl":"https://doi.org/10.18705/1607-419x-2022-28-2-126-146","url":null,"abstract":"","PeriodicalId":37695,"journal":{"name":"Arterial Hypertension (Russian Federation)","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82402486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Arterial Hypertension (Russian Federation)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1